1541 Stock Overview
A biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$11.76 |
52 Week High | HK$32.15 |
52 Week Low | HK$11.70 |
Beta | 0 |
11 Month Change | -8.84% |
3 Month Change | -21.07% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -39.75% |
Recent News & Updates
Health Check: How Prudently Does ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Use Debt?
Jun 10Shareholder Returns
1541 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -17.4% | 6.5% | -1.7% |
1Y | n/a | -26.3% | -5.9% |
Return vs Industry: Insufficient data to determine how 1541 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1541 performed against the Hong Kong Market.
Price Volatility
1541 volatility | |
---|---|
1541 Average Weekly Movement | 8.5% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 6.5% |
10% most volatile stocks in HK Market | 13.7% |
10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1541's share price has been volatile over the past 3 months.
Volatility Over Time: 1541's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 145 | Tian Wenzhi | www.immuneonco.com |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamentals Summary
1541 fundamental statistics | |
---|---|
Market cap | HK$4.40b |
Earnings (TTM) | -HK$412.55m |
Revenue (TTM) | HK$8.52m |
516.7x
P/S Ratio-10.7x
P/E RatioIs 1541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1541 income statement (TTM) | |
---|---|
Revenue | CN¥7.83m |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥7.83m |
Other Expenses | CN¥387.29m |
Earnings | -CN¥379.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.01 |
Gross Margin | 100.00% |
Net Profit Margin | -4,844.98% |
Debt/Equity Ratio | 8.0% |
How did 1541 perform over the long term?
See historical performance and comparison